Expression of fibronectin binding protein A (FnBPA) from Staphylococcus aureus at the cell surface of Lactococcus lactis improves its immunomodulatory properties when used as protein delivery vector

Vaccine

Volumn 34, Issue 10, 2016, Pages 1312-1318

  Almeida, Juliana F ^a,b   Breyner, Natalia M ^a,b   Mahi, Miloud ^a,c   Ahmed, Bensoltane ^c   Benbouziane, Bouasria ^a,d   Boas, Priscilla C B Vilas ^a,b   Miyoshi, Anderson ^b   Azevedo, Vasco ^b   Langella, Philippe ^a   Bermúdez Humarán, Luis G ^a   Chatel, Jean Marc ^a  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^c Biology Department   (Algeria)

^d UNIVERSITY OF MOSTAGANEM   (Algeria)

Author keywords

Fibronectin binding protein A (FnBPA); HPV 16 E7 antigen; Human papillomavirus (HPV); Lactic acid bacteria; Protein vaccination

Indexed keywords

BACTERIAL PROTEIN; FIBRONECTIN BINDING PROTEIN A; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G2A; INTERLEUKIN 10; INTERLEUKIN 12; LACTATE DEHYDROGENASE; PROTEIN E7; UNCLASSIFIED DRUG; ADHESIN; CANCER VACCINE; FIBRONECTIN-BINDING PROTEINS, BACTERIAL; ONCOGENE PROTEIN E7, HUMAN PAPILLOMAVIRUS TYPE 16;

ANIMAL EXPERIMENT; ARTICLE; CACO 2 CELL LINE; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNE RESPONSE; IMMUNOMODULATION; LACTOCOCCUS LACTIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN CELL; STAPHYLOCOCCUS AUREUS; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CELL SURFACE DISPLAY; CELLULAR IMMUNITY; FEMALE; HUMORAL IMMUNITY; IMMUNOLOGY; PAPILLOMAVIRUS INFECTIONS; PLASMID; TH1 CELL; TUMOR CELL LINE;

ADHESINS, BACTERIAL; ANIMALS; CACO-2 CELLS; CANCER VACCINES; CELL LINE, TUMOR; CELL SURFACE DISPLAY TECHNIQUES; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; LACTOCOCCUS LACTIS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS INFECTIONS; PLASMIDS; STAPHYLOCOCCUS AUREUS; T-LYMPHOCYTES, CYTOTOXIC; TH1 CELLS;

EID: 84958759455     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.01.022     Document Type: Article

References (32)

1. Chatel J.M., Pothelune L., Ah-Leung S., Corthier G., Wal J.M., Langella P. In vivo transfer of plasmid from food-grade transiting lactococci to murine epithelial cells. Gene Ther 2008, 15:1184-1190.
2. Guimaraes V.D., Innocentin S., Lefevre F., Azevedo V., Wal J.M., Langella P., et al. Use of native lactococci as vehicles for delivery of DNA into mammalian epithelial cells. Appl Environ Microbiol 2006, 72:7091-7097.
3. Wells J.M., Mercenier A. Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria. Nat Rev Microbiol 2008, 6:349-362.
4. Bermudez-Humaran L.G. Lactococcus lactis as a live vector for mucosal delivery of therapeutic proteins. Hum Vaccin 2009, 5:264-267.
5. Wells J.M. Immunomodulatory mechanisms of lactobacilli. Microb Cell Fact 2011, 10(1 Suppl):S17.
6. Rescigno M., Urbano M., Valzasina B., Francolini M., Rotta G., Bonasio R., et al. Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria. Nat Immunol 2001, 2:361-367.
7. Innocentin S., Guimaraes V., Miyoshi A., Azevedo V., Langella P., Chatel J.M., et al. Lactococcus lactis expressing either Staphylococcus aureus fibronectin-binding protein A or Listeria monocytogenes internalin A can efficiently internalize and deliver DNA in human epithelial cells. Appl Environ Microbiol 2009, 75:4870-4878.
8. Massey R.C., Kantzanou M.N., Fowler T., Day N.P., Schofield K., Wann E.R., et al. Fibronectin-binding protein A of Staphylococcus aureus has multiple, substituting, binding regions that mediate adherence to fibronectin and invasion of endothelial cells. Cell Microbiol 2001, 3:839-851.
9. Pontes D., Innocentin S., Del Carmen S., Almeida J.F., Leblanc J.G., de Moreno de Leblanc A., et al. Production of fibronectin binding protein A at the surface of Lactococcus lactis increases plasmid transfer in vitro and in vivo. PLoS One 2012, 7:e44892.
10. Almeida J.F., Mariat D., Azevedo V., Miyoshi A., de Moreno de LeBlanc A., Del Carmen S., et al. Correlation between fibronectin binding protein A expression level at the surface of recombinant Lactococcus lactis and plasmid transfer in vitro and in vivo. BMC Microbiol 2014, 14:248.
11. Pontes D., Azevedo M., Innocentin S., Blugeon S., Lefevre F., Azevedo V., et al. Immune response elicited by DNA vaccination using Lactococcus lactis is modified by the production of surface exposed pathogenic protein. PLoS One 2014, 9:e84509.
12. Ribelles P., Benbouziane B., Langella P., Suarez J.E., Bermudez-Humaran L.G. Protection against human papillomavirus type 16-induced tumors in mice using non-genetically modified lactic acid bacteria displaying E7 antigen at its surface. Appl Microbiol Biotechnol 2013, 97:1231-1239.
13. Bermudez-Humaran L.G., Langella P., Miyoshi A., Gruss A., Guerra R.T., Montes de Oca-Luna R., et al. Production of human papillomavirus type 16 E7 protein in Lactococcus lactis. Appl Environ Microbiol 2002, 68:917-922.
14. Bermudez-Humaran L.G., Cortes-Perez N.G., Le Loir Y., Alcocer-Gonzalez J.M., Tamez-Guerra R.S., de Oca-Luna R.M., et al. An inducible surface presentation system improves cellular immunity against human papillomavirus type 16 E7 antigen in mice after nasal administration with recombinant lactococci. J Med Microbiol 2004, 53:427-433.
15. Bermudez-Humaran L.G., Cortes-Perez N.G., Le Loir Y., Gruss A., Rodriguez-Padilla C., Saucedo-Cardenas O., et al. Fusion to a carrier protein and a synthetic propeptide enhances E7 HPV-16 production and secretion in Lactococcus lactis. Biotechnol Prog 2003, 19:1101-1104.
16. Kuipers O.P., de Ruyter P.G.G.A., Kleerebezem M., de Vos W.M. Quorum sensing-controlled gene expression in lactic acid bacteria. J Biotechnol 1998, 64:15-21.
17. Bermudez-Humaran L.G., Langella P., Cortes-Perez N.G., Gruss A., Tamez-Guerra R.S., Oliveira S.C., et al. Intranasal immunization with recombinant Lactococcus lactis secreting murine interleukin-12 enhances antigen-specific Th1 cytokine production. Infect Immun 2003, 71:1887-1896.
18. Cortes-Perez N.G., Bermudez-Humaran L.G., Le Loir Y., Rodriguez-Padilla C., Gruss A., Saucedo-Cardenas O., et al. Mice immunization with live lactococci displaying a surface anchored HPV-16 E7 oncoprotein. FEMS Microbiol Lett 2003, 229:37-42.
19. Enouf V., Langella P., Commissaire J., Cohen J., Corthier G. Bovine rotavirus nonstructural protein 4 produced by Lactococcus lactis is antigenic and immunogenic. Appl Environ Microbiol 2001, 67:1423-1428.
20. Le Loir Y., Gruss A., Ehrlich S.D., Langella P. A nine-residue synthetic propeptide enhances secretion efficiency of heterologous proteins in Lactococcus lactis. J Bacteriol 1998, 180:1895-1903.
21. Lutz M.B., Kukutsch N., Ogilvie A.L., Rossner S., Koch F., Romani N., et al. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 1999, 223:77-92.
22. Lin K.Y., Guarnieri F.G., Staveley-O'Carroll K.F., Levitsky H.I., August J.T., Pardoll D.M., et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 1996, 56:21-26.
23. de Azevedo M., Karczewski J., Lefevre F., Azevedo V., Miyoshi A., Wells J.M., et al. In vitro and in vivo characterization of DNA delivery using recombinant Lactococcus lactis expressing a mutated form of L. monocytogenes Internalin A. BMC Microbiol 2012, 12:299.
24. Watterlot L., Meyrand M., Gaide N., Kharrat P., Blugeon S., Gratadoux J.J., et al. Variations of N-acetylation level of peptidoglycan do not influence persistence of Lactococcus lactis in the gastrointestinal tract. Int J Food Microbiol 2010, 144:29-34.
25. Cortes-Perez N.G., Lefevre F., Corthier G., Adel-Patient K., Langella P., Bermudez-Humaran L.G. Influence of the route of immunization and the nature of the bacterial vector on immunogenicity of mucosal vaccines based on lactic acid bacteria. Vaccine 2007, 25:6581-6588.
26. Bermudez-Humaran L.G., Cortes-Perez N.G., Lefevre F., Guimaraes V., Rabot S., Alcocer-Gonzalez J.M., et al. A novel mucosal vaccine based on live Lactococci expressing E7 antigen and IL-12 induces systemic and mucosal immune responses and protects mice against human papillomavirus type 16-induced tumors. J Immunol 2005, 175:7297-7302.
27. Adachi K., Kawana K., Yokoyama T., Fujii T., Tomio A., Miura S., et al. Oral immunization with a Lactobacillus casei vaccine expressing human papillomavirus (HPV) type 16 E7 is an effective strategy to induce mucosal cytotoxic lymphocytes against HPV16 E7. Vaccine 2010, 28:2810-2817.
28. Kawana K., Adachi K., Kojima S., Taguchi A., Tomio K., Yamashita A., et al. Oral vaccination against HPV E7 for treatment of cervical intraepithelial neoplasia grade 3 (CIN3) elicits E7-specific mucosal immunity in the cervix of CIN3 patients. Vaccine 2014, 32:6233-6239.
29. Miyamoto Y.J., Wann E.R., Fowler T., Duffield E., Hook M., McIntyre B.W. Fibronectin binding protein A of Staphylococcus aureus can mediate human T lymphocyte adhesion and coactivation. J Immunol 2001, 166:5129-5138.
30. de Azevedo M., Meijerink M., Taverne N., Pereira V.B., LeBlanc J.G., Azevedo V., et al. Recombinant invasive Lactococcus lactis can transfer DNA vaccines either directly to dendritic cells or across an epithelial cell monolayer. Vaccine 2015, 33:4807-4812.
31. Olson B.M., McNeel D.G. Monitoring regulatory immune responses in tumor immunotherapy clinical trials. Front Oncol 2013, 3:109.
32. Moore K.W., de Waal Malefyt R., Coffman R.L., O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001, 19:683-765.